23andMe sold to Pharma company

Juke

Asagu/Asaga
VIP


Ignoring infrastructure, equipment, branding, etc. $256 million for a database of 15 million amounts to ~$17 per person.

No doubt this genomics-based pharma company is hoping to generate >$100/sample
 
They're going to use the data for research while maintaining the company's commercial consumer product setup.

The amount of data will give them refined information to produce better drug research, which is going to give them a pharmaceutical market cap increase. I said this a long time ago, 23andMe was initially set up to leverage the sample base to become what Regeneron is using it for, but it never reached there through its own business propagation.

23andMe had a good proof of concept, but the issue is that the revenue potential constantly sloped. Buying their services is not a continuous cash regenerative per person. Marketing potential for new users goes down because they get strapped for cash, and they have probably reached the limit of the customer potential. What I mean here is that within their marketing capacity, with limited finances. One can increase 23andMe's customers by marketing it heavily, though it costs money they do not have.
 

NidarNidar

♚kṯr w ḫss♚
VIP
I did not. I'm going in raw.

I got a message saying the data would be maintained in the same way by them, iirc. I'm curious if this new corporation will stimulate it and improve things. More refinement. 23andMe stopped updating chips for us for years. It was a letdown.
I never understood the fear of people, I'm excited to see what improvements they make.
 

NidarNidar

♚kṯr w ḫss♚
VIP
There are general concerns for these companies, sxb. They have a snapshot of your genetic data. One should think a couple of times before giving consent and have basic healthy skepticism.
If I were American, I would be more worried, but GDPR is very strict in the EU.
 

Juke

Asagu/Asaga
VIP
Did you delete your data?
Nah, this is close to the best possible scenario. 23andMe was already tryna do drug discovery but failed. The real disaster would've been a PE firm buying it then immediately licensing off the database to every possible entity that would've been interested be they health insurance companies seeking to mitigate risk or shady chinese biotech companies conducting underground experiments

You don't have permission to view the spoiler content. Log in or register now.
 

Juke

Asagu/Asaga
VIP
They're going to use the data for research while maintaining the company's commercial consumer product setup.

The amount of data will give them refined information to produce better drug research, which is going to give them a pharmaceutical market cap increase. I said this a long time ago, 23andMe was initially set up to leverage the sample base to become what Regeneron is using it for, but it never reached there through its own business propagation.

23andMe had a good proof of concept, but the issue is that the revenue potential constantly sloped. Buying their services is not a continuous cash regenerative per person. Marketing potential for new users goes down because they get strapped for cash, and they have probably reached the limit of the customer potential. What I mean here is that within their marketing capacity, with limited finances. One can increase 23andMe's customers by marketing it heavily, though it costs money they do not have.
You don't have permission to view the spoiler content. Log in or register now.
 

Trending

Latest posts

Top